MercachemSyncom changes name to Symeres - Gilde Healthcare

MercachemSyncom changes name to Symeres

November 19, 2020

MercachemSyncom changes name to Symeres

Nijmegen (The Netherlands) – MercachemSyncom today announced that it will change its name and operate under the registered trade name of Symeres.
 
The new name reflects the strategic evolution of the company, with the growth of integrated drug discovery and development services, which complement the company’s strong reputation in synthetic discovery and development chemistry. Recent examples of this evolution include the acquisition of ADME-Tox provider Admescope in November 2020 and strategic alliances integrating our services with high-quality CROs in the fields of in vitro biology, biophysics, and structural biology.
 
The name Symeres (derived from Sy-ncom Me-rcachem res-research) and accompanying tagline “making molecules matter” are derived from the experience and success of the Syncom and Mercachem legacy organizations and their core strengths in innovative research.
 
Dr. Eelco Ebbers, CEO of Symeres, added,

“The evolution of MercachemSyncom into Symeres is representative of the continuing expansion of the organization and our move into integrated solutions for drug discovery and development services, alongside our strong chemistry-centric services. The most recent example being our acquisition of Admescope. We look forward to continuing our journey with our clients around the world under our new identity, without forgetting the core values of quality, integrity, transparency, and innovation that got us to where we are today.”

For further information, please contact:
Dr. Russell Thomas
Head of Business Development
Symeres
Email: russell.thomas@symeres.com

 

About Symeres
Symeres, formerly MercachemSyncom, is the leading mid-sized European contract research organization offering innovative chemistry, medicinal chemistry, ADME, early process research services, and GMP production to accelerate the drug discovery and development process in a flexible and cost-effective way. Symeres also offers integrated drug-discovery services from hit to clinic via multiple-platform strategic alliances under a single MSA. Working for many pharmaceutical and biotech companies throughout the world, Symeres is recognized for its high-quality products and services and its unprecedented problem-solving capabilities.
For more information, please visit: www.symeres.com.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in fast growing companies active in digital health, medtech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study

Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit...
September 23, 2022

Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most...
September 12, 2022

Gilde Healthcare Company Volta Medical publishes clinical results on AI based solution for patients in atrial fibrillation

Volta Medical, a pioneering health tech company developing artificial intelligence (AI) software solutions to assist electrophysiologists to treat cardiac arrhythmias, announced that the Journal of Cardiovascular Electrophysiology (JCE) has published peer-reviewed results from the Company’s...
September 2, 2022